Gaining over 15,000 cases this 2024 and leading with the lowest survival rate for cancer types, lung cancer has been in the forefront of cancer cases in Australia. Biomarkers such ALK, ROS1, PD-L1, and BRAF are used in IHC and molecular laboratory techniques to identify specific types of lung cancer and guide targeted therapy.
HistoCyte tissue controls are a testament to precision and reliability in the diagnosis of breast cancer.
Asuragen’s Precision Oncology Solutions.
Revolutionising Precision Oncology with QuantideX®: Where Sensitivity Meets Scalability
Products are for professional/laboratory use only.
For 50 years, Bethyl has served the immunoassays community with high quality antibodies validated for applications like IHC, IP, WB and ICC.
Products are for professional/laboratory use only. With a comprehensive list of new Single Molecule Counting (SMC™), ELISA and SARS-CoV-2 kits, along with new instruments and xMAP® INTELLIFLEX Calibration and verification kits for RUO.
Products are for professional/laboratory use only.
A recent publication in the oncology field revealed that high blood levels of soluble OX40 indicate reduced survival in patients with advanced colorectal cancer (CRC).
Products are for professional/laboratory use only.
PRESS RELEASE: 28 August 2018
Mechelen, Belgium, 28 August 2018 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has obtained exclusive worldwide license rights for highly innovative EGFR ectodomain mutations that have shown to determine response to targeted therapy for patients with metastatic colorectal cancer1 (mCRC).